WSFS
BPMC

Wilmington Savings Fund Society’s Blueprint Medicines BPMC Stock Holding History

Wilmington Savings Fund Society’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5
Closed -$443 – 2063
2025
Q1 		$443 Hold
5
– – ﹤0.01% 2019
2024
Q4 		$436 Hold
5
– – ﹤0.01% 2043
2024
Q3 		$463 Buy
+5
New +$497 ﹤0.01% 2016

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wilmington Savings Fund Society's BPMC Position: Q2 2025 in Review

Wilmington Savings Fund Society sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 5 shares — an estimated $443 sold.

Wilmington Savings Fund Society first reported a position in BPMC in Q3 2024 and held it in 3 quarters. The position peaked at $463 in Q3 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Wilmington Savings Fund Society reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Wilmington Savings Fund Society sold 5 Blueprint Medicines shares in Q2 2025, an estimated $443.
  • Wilmington Savings Fund Society first reported a position in Blueprint Medicines in Q3 2024 and held it in 3 quarters.
  • Wilmington Savings Fund Society's Blueprint Medicines position peaked at $463 in Q3 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Wilmington Savings Fund Society's 13F filing for Q2 2025, filed 28 Jul 2025.